Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study Dermatology and Therapy February 2022;12(2):561-575
Date
02/01/2022
DOI
10.1007/s13555-021-00679-6Scopus ID
2-s2.0-85123243722 (requires institutional sign-in at Scopus site)
7 CitationsAuthor List
Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB
Author
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of Wisconsin